MX2016016449A - Modulacion de la actividad del complemento. - Google Patents
Modulacion de la actividad del complemento.Info
- Publication number
- MX2016016449A MX2016016449A MX2016016449A MX2016016449A MX2016016449A MX 2016016449 A MX2016016449 A MX 2016016449A MX 2016016449 A MX2016016449 A MX 2016016449A MX 2016016449 A MX2016016449 A MX 2016016449A MX 2016016449 A MX2016016449 A MX 2016016449A
- Authority
- MX
- Mexico
- Prior art keywords
- modulation
- complement activity
- modulators
- complement
- activity
- Prior art date
Links
- 230000024203 complement activation Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención provee moduladores de la actividad del sistema complemento. También se proveen métodos de utilización de los moduladores mencionados como terapéuticos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462011368P | 2014-06-12 | 2014-06-12 | |
US201462077460P | 2014-11-10 | 2014-11-10 | |
US201562108772P | 2015-01-28 | 2015-01-28 | |
PCT/US2015/035473 WO2015191951A2 (en) | 2014-06-12 | 2015-06-12 | Modulation of complement activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016016449A true MX2016016449A (es) | 2017-08-24 |
Family
ID=54834568
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016016449A MX2016016449A (es) | 2014-06-12 | 2015-06-12 | Modulacion de la actividad del complemento. |
MX2021009309A MX2021009309A (es) | 2014-06-12 | 2016-12-13 | Modulacion de la actividad del complemento. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009309A MX2021009309A (es) | 2014-06-12 | 2016-12-13 | Modulacion de la actividad del complemento. |
Country Status (28)
Country | Link |
---|---|
US (7) | US10106579B2 (es) |
EP (4) | EP4223317A3 (es) |
JP (4) | JP6432954B2 (es) |
KR (3) | KR102346228B1 (es) |
CN (2) | CN106456701B (es) |
AP (1) | AP2016009612A0 (es) |
AU (3) | AU2015274482B2 (es) |
BR (3) | BR122023024819A2 (es) |
CA (3) | CA2949985C (es) |
CY (2) | CY1122227T1 (es) |
DK (2) | DK3628680T3 (es) |
ES (2) | ES2895029T3 (es) |
FI (1) | FIC20240015I1 (es) |
HR (2) | HRP20211561T8 (es) |
HU (2) | HUE055931T2 (es) |
IL (3) | IL249093B (es) |
LT (2) | LT3628680T (es) |
MX (2) | MX2016016449A (es) |
NL (1) | NL301275I2 (es) |
NZ (3) | NZ727420A (es) |
PL (2) | PL3628680T3 (es) |
PT (2) | PT3628680T (es) |
RS (2) | RS62428B1 (es) |
RU (1) | RU2670988C2 (es) |
SG (1) | SG11201610222UA (es) |
SI (2) | SI3628680T1 (es) |
WO (1) | WO2015191951A2 (es) |
ZA (3) | ZA201706379B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4223317A3 (en) | 2014-06-12 | 2023-09-27 | RA Pharmaceuticals, Inc. | Modulation of complement activity |
EP3988110A1 (en) | 2015-01-28 | 2022-04-27 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
MX2018007352A (es) | 2015-12-16 | 2019-05-16 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
US11026945B2 (en) | 2016-04-29 | 2021-06-08 | The Trustees Of The University Of Pennsylvania | Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation |
BR112019011053A2 (pt) * | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
WO2019246405A1 (en) | 2018-06-21 | 2019-12-26 | Merck Sharp & Dohme Corp. | Cyclic polypeptides for pcsk9 inhibition |
WO2019246386A1 (en) | 2018-06-21 | 2019-12-26 | Ra Pharmaceuticals Inc. | Cyclic polypeptides for pcsk9 inhibition |
US11814445B2 (en) * | 2018-06-21 | 2023-11-14 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for PCSK9 inhibition |
SG11202103972SA (en) * | 2018-10-22 | 2021-05-28 | Ra Pharmaceuticals Inc | Neurological disease treatment with zilucoplan |
CN113543796A (zh) | 2019-03-08 | 2021-10-22 | Ra制药公司 | 齐鲁考普作为深层组织穿透性c5抑制剂 |
BR112021017820A2 (pt) * | 2019-04-24 | 2022-02-08 | Ra Pharmaceuticals Inc | Composições e métodos para modulação da atividade de complemento |
CN113966224A (zh) | 2019-06-04 | 2022-01-21 | Ra制药公司 | 采用补体抑制剂的炎性疾病治疗 |
EP4028126A1 (en) | 2019-09-12 | 2022-07-20 | RA Pharmaceuticals, Inc. | Neurological disease treatment with complement inhibitors |
US11932705B2 (en) | 2020-12-18 | 2024-03-19 | Merck Sharp & Dohme Llc | Cyclic polypeptides for PCSK9 inhibition |
EP4281464A1 (en) | 2021-01-20 | 2023-11-29 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
WO2022177635A2 (en) * | 2021-02-22 | 2022-08-25 | Ra Pharmaceuticals, Inc. | Compositions and methods for microbial disease treatment |
WO2023215294A1 (en) * | 2022-05-02 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | Complement pathway inhibition for wound healing |
WO2024039636A1 (en) * | 2022-08-16 | 2024-02-22 | Ps Therapy, Inc. | Methods of use for disulfiram and metabolites thereof |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4271068A (en) | 1968-05-10 | 1981-06-02 | Ciba-Geigy Corporation | Process for the manufacture of cystine-containing peptides |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4033940A (en) | 1975-11-12 | 1977-07-05 | Armour Pharmaceutical Company | Cyclization of peptides |
US4216141A (en) | 1978-07-19 | 1980-08-05 | The Salk Institute For Biological Studies | Method for cyclization of peptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5371109A (en) | 1986-07-01 | 1994-12-06 | Drilletten Ab | Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
JP3127158B2 (ja) | 1989-10-05 | 2001-01-22 | オプテイン,インコーポレイティド | 新規の遺伝子及びポリペチドの無細胞合成並びに単離 |
US5585353A (en) | 1990-02-02 | 1996-12-17 | The Rockefeller University | Antibiotic peptides containing D-amino acids |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US5843701A (en) | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
JPH08510325A (ja) | 1993-05-28 | 1996-10-29 | カイロン コーポレイション | 生物学的に活性なペプチド配列の選択方法 |
DK0710243T3 (da) | 1993-06-29 | 2000-10-16 | Ferring Bv | Syntese af cykliske peptider |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5834318A (en) | 1995-05-10 | 1998-11-10 | Bayer Corporation | Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
US6720472B2 (en) | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6348584B1 (en) | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
EP0962527B1 (en) | 1996-10-17 | 2004-08-04 | Mitsubishi Chemical Corporation | Molecule that homologizes genotype and phenotype and utilization thereof |
US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
EP0971946B1 (en) | 1997-01-21 | 2006-07-05 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
EP0896001A1 (en) | 1997-08-08 | 1999-02-10 | Daicel Chemical Industries, Ltd. | Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates |
US6429301B1 (en) | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
IL140930A0 (en) | 1998-08-07 | 2002-02-10 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
WO2000021559A2 (en) | 1998-10-09 | 2000-04-20 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
US6962781B1 (en) | 2000-05-19 | 2005-11-08 | Proteonova, Inc. | In vitro evolution of nucleic acids and encoded polypeptide |
US7244701B2 (en) | 2000-06-16 | 2007-07-17 | Zealand Phama A/S | Diuretic peptide conjugate |
WO2004035624A2 (en) * | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
CA2524534C (en) | 2003-05-15 | 2012-12-11 | Sek Chung Fung | Methods and compositions for the prevention and treatment of sepsis |
US7348401B2 (en) | 2003-09-10 | 2008-03-25 | Innate Biotech, Inc. | Peptides that inhibit complement activation |
CA2537029C (en) | 2003-11-26 | 2013-03-12 | Likan Liang | Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
US20060027059A1 (en) | 2004-08-09 | 2006-02-09 | Chih-Ching Hsien | Extendable handle device |
US20090054623A1 (en) * | 2004-12-17 | 2009-02-26 | Neose Technologies, Inc. | Lipo-Conjugation of Peptides |
PT1844337E (pt) | 2005-01-24 | 2014-04-03 | Pepscan Systems Bv | Compostos ligantes, compostos imunogénicos e peptidomiméticos |
EP1874289A2 (en) | 2005-03-29 | 2008-01-09 | Cardax Pharmaceuticals, Inc. | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
JP5707024B2 (ja) | 2005-05-26 | 2015-04-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤 |
DK1888031T3 (da) | 2005-06-06 | 2013-02-18 | Camurus Ab | GLP-1-analogformuleringer |
KR20170002684A (ko) | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
EP1876183A1 (en) * | 2006-07-04 | 2008-01-09 | Technische Universität München | Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins |
US8703136B2 (en) | 2006-10-10 | 2014-04-22 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
US7736860B2 (en) | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
JP2010520309A (ja) | 2007-03-06 | 2010-06-10 | ノボ・ノルデイスク・エー/エス | 出血関連性炎症を治療するための補体系活性化の調節 |
CA2680760A1 (en) | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
US20100015139A1 (en) | 2008-07-10 | 2010-01-21 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
JP2010526074A (ja) | 2007-04-30 | 2010-07-29 | アルコン リサーチ, リミテッド | 補体因子dのインヒビターを用いる加齢黄斑変性の処置 |
KR20150029002A (ko) | 2007-06-07 | 2015-03-17 | 제넨테크, 인크. | 보체-관련 장애의 예방 및 치료를 위한 C3b 항체 및 방법 |
US20110142837A1 (en) | 2007-07-20 | 2011-06-16 | Trustees Of The University Of Pennsylvania | Method Of Treating Acute Respiratory Distress Syndrome |
KR20150080007A (ko) | 2007-10-02 | 2015-07-08 | 포텐시아 팔마큐티칼스, 인크. | 겔로부터 콤스타틴 유사체의 지속적 운반 |
WO2009067191A2 (en) | 2007-11-16 | 2009-05-28 | The General Hospital Corporation | Methods and compositions for the treatment of hepatitis c virus (hcv) infection |
US20110190221A1 (en) | 2008-03-28 | 2011-08-04 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
EP2324048A2 (en) | 2008-07-30 | 2011-05-25 | Cosmix Therapeutics Llc | Peptide therapeutics that bind vegf and methods of use thereof |
EP2815766B1 (en) * | 2008-08-05 | 2017-07-05 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
AU2009290137A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
PT2894165T (pt) | 2008-11-10 | 2023-03-17 | Alexion Pharma Inc | Métodos e composições para o tratamento de distúrbios associados ao complemento |
AU2009230735B1 (en) | 2009-01-08 | 2010-01-21 | Shane Ramodien | Electronic equipment housing |
CN106390117A (zh) | 2009-10-16 | 2017-02-15 | 奥默罗斯公司 | 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法 |
CN102958535A (zh) | 2009-11-05 | 2013-03-06 | 亚力史剑桥公司 | 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗 |
WO2011073328A1 (en) | 2009-12-16 | 2011-06-23 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
US9172511B2 (en) | 2009-12-24 | 2015-10-27 | Samsung Electronics Co., Ltd. | Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network |
US9358266B2 (en) | 2010-02-25 | 2016-06-07 | The Trustees Of The University Of Pennsylvania | Treatment of sepsis using complement inhibitors |
WO2011112999A2 (en) | 2010-03-12 | 2011-09-15 | The Regents Of The University Of California | Lipid-peptide-polymer conjugates and nanoparticles thereof |
WO2011139343A2 (en) * | 2010-04-28 | 2011-11-10 | Wu Nian | Amino acid linked peg-lipid conjugates |
WO2011137363A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
EP2694108B1 (en) | 2011-04-08 | 2018-06-06 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
WO2012162215A1 (en) | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
WO2012174055A1 (en) | 2011-06-13 | 2012-12-20 | The Trustees Of The University Of Pennsylvania | Wound healing using complement inhibitors |
CN102321170B (zh) * | 2011-09-14 | 2013-11-13 | 深圳翰宇药业股份有限公司 | 利拉鲁肽变构体及其缀合物 |
WO2013052736A2 (en) * | 2011-10-06 | 2013-04-11 | The Medicines Company | Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010 |
WO2013126006A1 (en) | 2012-02-20 | 2013-08-29 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement c5 |
US20130246083A1 (en) | 2012-03-16 | 2013-09-19 | Alexion Pharmaceuticals, Inc. | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
CA2873511A1 (en) | 2012-05-17 | 2013-11-21 | Ra Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
US20130345257A1 (en) | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
US20150330989A1 (en) | 2012-11-15 | 2015-11-19 | The Brigham And Women's Hospital, Inc. | Method and system for diagnosing and treating preeclampsia |
US9700633B2 (en) * | 2013-01-28 | 2017-07-11 | Jenkem Technology Co., Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
US20140234275A1 (en) | 2013-02-15 | 2014-08-21 | Jason Williams | Method for treating als via the increased production of factor h |
US20150057342A1 (en) | 2013-08-21 | 2015-02-26 | Cannabics Pharmaceuticals Inc | Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
WO2015140304A1 (en) | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
EP4223317A3 (en) | 2014-06-12 | 2023-09-27 | RA Pharmaceuticals, Inc. | Modulation of complement activity |
WO2016094834A2 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
WO2016118652A1 (en) | 2015-01-21 | 2016-07-28 | Pacira Pharmaceuticals, Inc. | Multivesicular liposome formulations of tranexamic acid |
EP3988110A1 (en) * | 2015-01-28 | 2022-04-27 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
WO2017035362A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
MX2018007352A (es) | 2015-12-16 | 2019-05-16 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
US20200282024A1 (en) | 2017-09-11 | 2020-09-10 | Ra Pharmaceuticals, Inc. | Formulations for compound delivery |
CN111683672A (zh) | 2017-12-04 | 2020-09-18 | Ra制药公司 | 补体活性调节剂 |
CN113543796A (zh) | 2019-03-08 | 2021-10-22 | Ra制药公司 | 齐鲁考普作为深层组织穿透性c5抑制剂 |
BR112021017820A2 (pt) | 2019-04-24 | 2022-02-08 | Ra Pharmaceuticals Inc | Composições e métodos para modulação da atividade de complemento |
-
2015
- 2015-06-12 EP EP23165319.7A patent/EP4223317A3/en active Pending
- 2015-06-12 SI SI201531715T patent/SI3628680T1/sl unknown
- 2015-06-12 KR KR1020197014115A patent/KR102346228B1/ko active IP Right Grant
- 2015-06-12 CA CA2949985A patent/CA2949985C/en active Active
- 2015-06-12 EP EP19194070.9A patent/EP3628680B1/en active Active
- 2015-06-12 LT LTEP19194070.9T patent/LT3628680T/lt unknown
- 2015-06-12 PT PT19194070T patent/PT3628680T/pt unknown
- 2015-06-12 HU HUE19194070A patent/HUE055931T2/hu unknown
- 2015-06-12 EP EP15807069.8A patent/EP3154561B1/en active Active
- 2015-06-12 AU AU2015274482A patent/AU2015274482B2/en active Active
- 2015-06-12 DK DK19194070.9T patent/DK3628680T3/da active
- 2015-06-12 RU RU2016147080A patent/RU2670988C2/ru active
- 2015-06-12 EP EP21192106.9A patent/EP3973994A1/en active Pending
- 2015-06-12 SI SI201530933T patent/SI3154561T1/sl unknown
- 2015-06-12 CA CA3241273A patent/CA3241273A1/en active Pending
- 2015-06-12 ES ES19194070T patent/ES2895029T3/es active Active
- 2015-06-12 CN CN201580031341.8A patent/CN106456701B/zh active Active
- 2015-06-12 BR BR122023024819-8A patent/BR122023024819A2/pt unknown
- 2015-06-12 ES ES15807069T patent/ES2750556T3/es active Active
- 2015-06-12 NZ NZ727420A patent/NZ727420A/en unknown
- 2015-06-12 RS RS20211214A patent/RS62428B1/sr unknown
- 2015-06-12 BR BR122021025449-4A patent/BR122021025449B1/pt active IP Right Grant
- 2015-06-12 US US15/318,063 patent/US10106579B2/en active Active
- 2015-06-12 WO PCT/US2015/035473 patent/WO2015191951A2/en active Application Filing
- 2015-06-12 BR BR112016029076-3A patent/BR112016029076B1/pt active IP Right Grant
- 2015-06-12 RS RSP20191263 patent/RS59353B1/sr unknown
- 2015-06-12 AP AP2016009612A patent/AP2016009612A0/en unknown
- 2015-06-12 NZ NZ736573A patent/NZ736573A/en unknown
- 2015-06-12 HU HUE15807069A patent/HUE045646T2/hu unknown
- 2015-06-12 NZ NZ761610A patent/NZ761610A/en unknown
- 2015-06-12 PL PL19194070T patent/PL3628680T3/pl unknown
- 2015-06-12 PT PT158070698T patent/PT3154561T/pt unknown
- 2015-06-12 DK DK15807069.8T patent/DK3154561T3/da active
- 2015-06-12 HR HRP20211561TT patent/HRP20211561T8/hr unknown
- 2015-06-12 LT LT15807069T patent/LT3154561T/lt unknown
- 2015-06-12 KR KR1020217042686A patent/KR102503319B1/ko active IP Right Grant
- 2015-06-12 SG SG11201610222UA patent/SG11201610222UA/en unknown
- 2015-06-12 JP JP2017517219A patent/JP6432954B2/ja active Active
- 2015-06-12 CA CA3174909A patent/CA3174909A1/en active Pending
- 2015-06-12 CN CN202010020678.1A patent/CN111187338A/zh active Pending
- 2015-06-12 PL PL15807069T patent/PL3154561T3/pl unknown
- 2015-06-12 MX MX2016016449A patent/MX2016016449A/es unknown
- 2015-06-12 KR KR1020167034788A patent/KR101981532B1/ko active IP Right Grant
-
2016
- 2016-11-21 IL IL249093A patent/IL249093B/en active IP Right Grant
- 2016-12-13 MX MX2021009309A patent/MX2021009309A/es unknown
-
2017
- 2017-09-21 ZA ZA2017/06379A patent/ZA201706379B/en unknown
-
2018
- 2018-09-12 US US16/128,561 patent/US10208089B2/en active Active
- 2018-10-31 JP JP2018204571A patent/JP6770043B2/ja active Active
-
2019
- 2019-01-02 US US16/237,893 patent/US10435438B2/en active Active
- 2019-01-24 ZA ZA201900497A patent/ZA201900497B/en unknown
- 2019-02-07 AU AU2019200828A patent/AU2019200828B2/en active Active
- 2019-08-29 US US16/554,665 patent/US10562934B2/en active Active
- 2019-09-27 HR HRP20191763TT patent/HRP20191763T1/hr unknown
- 2019-10-07 CY CY20191101050T patent/CY1122227T1/el unknown
-
2020
- 2020-01-02 US US16/732,502 patent/US11014965B2/en active Active
- 2020-03-24 ZA ZA2020/01859A patent/ZA202001859B/en unknown
- 2020-04-01 IL IL273746A patent/IL273746B/en active IP Right Grant
- 2020-05-15 JP JP2020085588A patent/JP7002597B2/ja active Active
-
2021
- 2021-03-04 IL IL281264A patent/IL281264B/en unknown
- 2021-04-21 US US17/236,247 patent/US11965040B2/en active Active
- 2021-06-24 AU AU2021204313A patent/AU2021204313B2/en active Active
- 2021-10-15 CY CY20211100898T patent/CY1124595T1/el unknown
- 2021-12-27 JP JP2021212477A patent/JP7454545B2/ja active Active
-
2022
- 2022-04-19 US US17/724,304 patent/US11535650B1/en active Active
-
2024
- 2024-05-24 NL NL301275C patent/NL301275I2/nl unknown
- 2024-05-28 FI FIC20240015C patent/FIC20240015I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009309A (es) | Modulacion de la actividad del complemento. | |
PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
MX2017016405A (es) | Reguladores de nrf2. | |
MX2022013454A (es) | Moduladores de la actividad del complemento. | |
MX2017003359A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
IN2015DE00625A (es) | ||
MX2020007742A (es) | Procesos para preparar fluorocetolidos. | |
UA104671U (uk) | Застосування яктону як нейропротектора | |
AU356752S (en) | Point of sale unit | |
IN2014MU03184A (es) | ||
IN2014CH00927A (es) |